Free Trial

CytoDyn (OTCMKTS:CYDY) Shares Down 1% - Here's Why

CytoDyn logo with Medical background

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was down 1% during trading on Friday . The company traded as low as $0.29 and last traded at $0.32. Approximately 972,342 shares changed hands during trading, a decline of 34% from the average daily volume of 1,481,894 shares. The stock had previously closed at $0.32.

CytoDyn Trading Down 2.4%

The stock has a fifty day moving average of $0.34 and a 200-day moving average of $0.26.

About CytoDyn

(Get Free Report)

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Featured Stories

Should You Invest $1,000 in CytoDyn Right Now?

Before you consider CytoDyn, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.

While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines